Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

8.200 +2.390 (+41.13%)
Streaming Delayed Price Updated: 11:34 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
From Compass Pathfinder Limited
Via Business Wire
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
From Compass Pathfinder Limited
Via Business Wire
News headline image
Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge. 
Via Stocktwits
Topics ETFs
News headline image
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Two Investor Conferences in December
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Stifel 2025 Healthcare Conference
From Compass Pathfinder Limited
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
From Compass Pathfinder Limited
Via Business Wire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Four Investor Conferences in September
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass (CMPS) Q2 Loss Improves 27% ↗
Via The Motley Fool
News headline image
Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
From Compass Pathfinder
Via Business Wire
News headline image
Compass Pathways Appoints Justin Gover to Board of Directors
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025
From Compass Pathfinder Limited
Via Business Wire
News headline image
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? ↗
Via The Motley Fool
News headline image
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
From Compass Pathfinder Limited
Via Business Wire
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.